(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
This volume focuses on therapeutic targets that were identified after TNF blockade. All these targets have recently been registered or are currently under development for the treatment of rheumatoid arthritis. Each chapter explores the biological rationale of a distinct therapeutic target in great detail. Readers will discover the latest in vitro work, animal models, and results from clinical trials.
Contents:
B cell targets in rheumatoid arthritis.- Co-stimulatory pathways in the therapy of rheumatoid arthritis.- Immunobiology of IL-6 - Tocilizumab (Humanized anti-IL-6 receptor antibody ) for the treatment of RA.- Role of IL-1 in erosive arthritis, lessons from animal models.- Interleukin-15.- IL-17 and Th17 cells, key players in arthritis.- Role of il-18 in inflammatory diseases.- Chemokines and chemokine receptors.- Signaling pathways in rheumatoid arthritis.- Targeting oncostatin M in the treatment of rheumatoid arthritis.- Targeting the epigenetic modifications of synovial cells.- Perspectives in targeted therapy.
PRODUCT DETAILS
Publisher: Springer (Birkhauser Verlag AG)
Publication date: March, 2009
Pages: 237
Weight: 591g
Availability: Available
Subcategories: Immunology, Orthopaedics and Fractures, Pharmacology, Rheumatology
From the same series
